Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure–In Vitro (Pharmacology–ADME)–In Vivo (Safety) Relationships

[1]  Jean Sallantin,et al.  A Pragmatic Logic of Scientific Discovery , 2006, Discovery Science.

[2]  A. Fliri,et al.  Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.

[3]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[4]  Dragos Horvath,et al.  Neighborhood Behavior of in Silico Structural Spaces with Respect to In Vitro Activity Spaces-A Benchmark for Neighborhood Behavior Assessment of Different in Silico Similarity Metrics , 2003, J. Chem. Inf. Comput. Sci..

[5]  A. Methner,et al.  Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands , 2002, Genome Biology.

[6]  A. Fliri,et al.  Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[8]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[9]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[10]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[11]  Dragos Horvath,et al.  QSAR Strategy and Experimental Validation for the Development of a GPCR Focused Library , 2005 .

[12]  Dragos Horvath,et al.  Neighborhood Behavior of in Silico Structural Spaces with Respect to in Vitro Activity Spaces-A Novel Understanding of the Molecular Similarity Principle in the Context of Multiple Receptor Binding Profiles , 2003, J. Chem. Inf. Comput. Sci..

[13]  Tomas Mustelin,et al.  Positive and negative regulation of T-cell activation through kinases and phosphatases. , 2003, The Biochemical journal.

[14]  Jean Sallantin,et al.  Multiobjective/Multicriteria Optimization and Decision Support in Drug Discovery , 2007 .

[15]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[16]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[17]  Q. Cao,et al.  4.32 – Biological Fingerprints , 2007 .

[18]  N. Froloff,et al.  Construction of a Homogeneous and Informative In vitro Profiling Database for Anticipating the Clinical Effects of Drugs , 2006 .

[19]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[20]  A. Fliri,et al.  Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. , 2005, Journal of medicinal chemistry.

[21]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.